Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo Leaf Extract and Armillariella Mellea Powder for Motoric Cognitive Risk Syndrome
NCT04492241Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Yinxingmihuan in Motoric Cognitive Risk Syndrome (MCR) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 6 months. Status: unknown.
02
Drugs
Yinxingmihuan
03
Conditions
Motoric Cognitive Risk Syndrome (MCR)
Beyond the preview
Go deeper on NCT04492241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492241.